Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Express Scripts
Mallinckrodt
Boehringer Ingelheim
Dow

Last Updated: December 5, 2019

DrugPatentWatch Database Preview

Litigation Details for Insys Therapeutics, Inc. v. Alkem Laboratories Ltd. (D. Del. 2017)

See Plans and Pricing

« Back to Dashboard

Insys Therapeutics, Inc. v. Alkem Laboratories Ltd. (D. Del. 2017)

Docket   Start Trial Date Filed 2017-10-10
Court District Court, D. Delaware Date Terminated 2018-07-13
Cause 35:271 Patent Infringement Assigned To Leonard Philip Stark
Jury Demand Defendant Referred To
Parties ALKEM LABORATORIES LTD.; INSYS DEVELOPMENT COMPANY, INC.; INSYS THERAPEUTICS, INC.; S&B PHARMA, INC.; S&B PHARMA, INC.
Patents 8,222,292; 9,345,771
Attorneys Chad J. Peterman; Gerald J. Flattmann , Jr.; Jack B. Blumenfeld; Kevin M. Capuzzi; Lucas L. Kressel; Maryellen Noreika; Michael A. Stramiello; Naveen Modi; Stephen M. Ferguson; Zaiba Baig
Firms Benesch Friedlander Coplan & Aronoff LLP; Morris, Nichols, Arsht & Tunnell
Link to Docket External link to docket
Small Molecule Drugs cited in Insys Therapeutics, Inc. v. Alkem Laboratories Ltd.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Insys Therapeutics, Inc. v. Alkem Laboratories Ltd. (D. Del. 2017)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 1 United States Patent Nos. 8,222,292 (“the ’292 patent”) and 9,345,771 (“the ’771 patent”); (collectively…collectively, “the patents-in-suit”). This action arises under the Patent Laws of the United States, 35 U.S.… the ’292 patent is attached as Exhibit A. 18. Insys Dev owns the ’292 patent. 19… the ’771 patent is attached as Exhibit B. 20. Insys Dev owns the ’771 patent. 21…claims of the patents-in-suit. Alkem’s Infringement of the Patents-In-Suit External link to document
0000-00-00 4 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,222,292 B2; 9,345,771 B2. (…2017 13 July 2018 1:17-cv-01419 835 Patent - Abbreviated New Drug Application(ANDA) External link to document
0000-00-00 41 Patent/Trademark Report to Commissioner of Patents the Commissioner of Patents and Trademarks for Patent/Trademark Numbers 8,222,292 B2 ;9,345,771 B2. (etg…2017 13 July 2018 1:17-cv-01419 835 Patent - Abbreviated New Drug Application(ANDA) External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Boehringer Ingelheim
Colorcon
Medtronic
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.